Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers.

JCO precision oncology - 1 Dec 2024

Gelfer Rebecca, Gulla Aiste, Kalvin Hannah L, Song Yi, Harding James, Abou-Alfa Ghassan K, O'Reilly Eileen M, Park Wungki, Chandwani Rohit, Wei Alice, Kingham Peter, Drebin Jeffrey, Balachandran Vinod, D'Angelica Michael, Soares Kevin, Gonen Mithat, Jarnagin William R

Abstract excerpt

PURPOSE: KRAS variants are associated with poor outcomes in biliary tract cancers (BTCs). This study assesses the prevalence of KRAS variants and their association with survival and recurrence in patients with intrahepatic cholangiocarcinoma (IHC), extrahepatic cholangiocarcinoma (EHC), and gallbladder adenocarcinoma (GB). METHODS: In this cross-sectional, single-institution study at Memorial Sloan Kettering,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to Cross-Sectional Studies

Share to BTC gene

Share to SF3B1 gene

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 39642327
DOI: 10.1200/PO.24.00263
PMCID: PMC12305477

Genes

KRAS
BTC
SF3B1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers.PMID 39642327Read ↗

KRAS Allelic Variants in Biliary Tract Cancers.Semantic proximity Read ↗

Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.Semantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Immune checkpoint inhibitor-related molecular markers predict prognosis in extrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Genomic Profiling of Biliary Tract Cancers: Comprehensive Assessment of Anatomic and Geographic Heterogeneity, Co‐Alterations and OutcomesSemantic proximity Read ↗

KRAS Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and KRAS G12/G13 Detection in Cell-Free DNA.Semantic proximity Read ↗

Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations.Semantic proximity Read ↗

Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer.Semantic proximity Read ↗

Global patterns of mutational profiles in biliary tract cancer.Semantic proximity Read ↗

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.Semantic proximity Read ↗

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.